Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of conjunctival hyperemia with Lumigan 0.01% vs Xalatan 0.005% in glaucoma or ocular hypertension
2010-020213-82Phase 3Terminated
- Sponsor
- Fondazione G.B. Bietti-IRCCS
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Glaucoma and ocular hypertension comparing Lumigan arm with Xalatan arm (2 arms). Primary endpoint: Incidence and severity of conjunctival hyperemia. Started Sep 2010; status: terminated.
02
Drugs
bimatoprostlatanoprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2010-020213-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020213-82.